<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888093</url>
  </required_header>
  <id_info>
    <org_study_id>201607769</org_study_id>
    <nct_id>NCT02888093</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension</brief_title>
  <official_title>A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Kowalski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Urogynecological Association (IUGA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterosacral ligament suspension (USLS) is a commonly performed, vaginal surgery for the
      correction of female pelvic organ prolapse. The original description of this procedure
      included the use of permanent sutures. However, permanent suture use in this vaginal
      application can result in some minor complication such as persistent vaginal spotting,
      vaginal discharge and dyspareunia. Subsequent reports on this procedure have utilized
      delayed-absorbable sutures in order to avoid these complications. Retrospective studies are
      conflicting as to whether or not absorbable suture provides as durable an anatomic outcome as
      permanent suture. There are currently no high-quality, prospective studies that have
      evaluated outcomes of permanent and absorbable suture for uterosacral ligament suspension.

      This study will recruit women scheduled to undergo USLS with or without other prolapse or
      anti-incontinence procedures. Participants will be randomized 1:1 to permanent or absorbable
      suture. Follow up will occur at 6 weeks and 12 months post-operatively. The primary outcome
      will be Pelvic Organ Prolapse Quantification Exam (POP-Q) point C as measured at the 12 month
      follow up visit. Subjects and assessors will be blinded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient demographics, relevant histories, baseline physical exam including POP-Q and PFDI-20
      data will be abstracted from the electronic medical record following enrollment. This
      information will be placed into a secure database.

      The randomization sequence will be generated by randomize.net, a web-based service that
      provides comprehensive randomization services for randomized controlled trials. The sequence
      will be randomized 1:1 with blocks of 4 and stratified by surgeon. Concealment will be
      completely opaque as group allocation will not be revealed until the subject is enrolled on
      the web-based service and the surgeon has elected to randomize the patient from an internet
      connection in the operating room.

      Subjects and assessors will be blinded to study group. The surgeons will, necessarily, not be
      blinded. Subjects will only be informed of their assigned group upon request following
      completion of the entire study.

      USLS with the assigned suture and any scheduled concomitant prolapse and anti-incontinence
      procedures will be performed. All procedures will be performed by one of two
      fellowship-trained, Female Pelvic Medicine and Reconstructive Surgery board-certified
      surgeons. USLS will be performed as initially described by Shull et al with two important
      differences in technique. First, 2 sutures will be placed through the intermediate portion of
      each uterosacral ligament instead of 3. Second, when absorbable suture (polydioxanone) is
      used, the suture will be placed through the full thickness of the anterior and posterior
      vaginal walls.

      Follow up exams will occur at 6 weeks and 12 months post-operatively and will include a POP-Q
      exam. The 6 week follow up visit will include the Patient Global Impression of Improvement
      (PGI-I) and an additional survey. The 12 month follow up visit will include a the PGI-I,
      PFDI-20 and an additional survey. All participants will also be assessed for any
      suture-related complications, such as erosion or granulation tissue. Follow up exams will be
      completed by one of two urogynecology nurse practitioners who will be blinded to the surgery
      and suture choice. Both nurse practitioners have extensive experience in performing POP-Q
      exams. The examiners will complete a follow up data abstraction form for each follow up
      appointment (6 weeks and 12 months).

      The follow up clinic appointments at 6 weeks and 12 months are the times of usually scheduled
      post-operative follow up for USLS procedures. Additionally, completion of the PFDI-20
      questionnaire and a POP-Q exam constitute routine clinical care for these patients. As such,
      there is no additional time commitment for subjects compared to routine clinical care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C</measure>
    <time_frame>12 months</time_frame>
    <description>Non-inferiority of POP-Q point C. This measure was obtained as originally described by Bump et al. The hymen is used as a fixed reference point. In other words, this is point zero. Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suture-related Complications</measure>
    <time_frame>6 weeks and 12 months</time_frame>
    <description>The presence of apical granulation tissue, apical suture exposure, abnormal vaginal discharge, vaginal spotting, post-coital spotting, dyspareunia or patient being able to feel suture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Prolapse Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Positive response to PFDI-20 question #3 regarding the presence of a vaginal bulge (yes) AND the presence of bother (somewhat, moderately or quite a bit).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Cystocele</condition>
  <condition>Uterine Prolapse</condition>
  <arm_group>
    <arm_group_label>Absorbable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Permanent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</intervention_name>
    <arm_group_label>Absorbable</arm_group_label>
    <arm_group_label>Permanent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for uterosacral ligament suspension (USLS)

        Exclusion Criteria:

          -  Non-English speaking

          -  Prisoner

          -  Cognitive impairment precluding informed consent

          -  Planned hysteropexy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph T Kowalski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <results_first_submitted>October 11, 2019</results_first_submitted>
  <results_first_submitted_qc>November 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2019</results_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Joseph Kowalski</investigator_full_name>
    <investigator_title>Female Pelvic Medicine and Reconstructive Surgery, Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02888093/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Absorbable</title>
          <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
        </group>
        <group group_id="P2">
          <title>Permanent</title>
          <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorbable</title>
          <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
        </group>
        <group group_id="B2">
          <title>Permanent</title>
          <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="13.7"/>
                    <measurement group_id="B2" value="63.6" spread="10.2"/>
                    <measurement group_id="B3" value="62.9" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C</title>
        <description>Non-inferiority of POP-Q point C. This measure was obtained as originally described by Bump et al. The hymen is used as a fixed reference point. In other words, this is point zero. Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorbable</title>
            <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
          </group>
          <group group_id="O2">
            <title>Permanent</title>
            <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
          </group>
        </group_list>
        <measure>
          <title>Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C</title>
          <description>Non-inferiority of POP-Q point C. This measure was obtained as originally described by Bump et al. The hymen is used as a fixed reference point. In other words, this is point zero. Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.</description>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" lower_limit="-9" upper_limit="-5.5"/>
                    <measurement group_id="O2" value="-7" lower_limit="-10" upper_limit="-6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suture-related Complications</title>
        <description>The presence of apical granulation tissue, apical suture exposure, abnormal vaginal discharge, vaginal spotting, post-coital spotting, dyspareunia or patient being able to feel suture.</description>
        <time_frame>6 weeks and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorbable</title>
            <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)</description>
          </group>
          <group group_id="O2">
            <title>Permanent</title>
            <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)</description>
          </group>
        </group_list>
        <measure>
          <title>Suture-related Complications</title>
          <description>The presence of apical granulation tissue, apical suture exposure, abnormal vaginal discharge, vaginal spotting, post-coital spotting, dyspareunia or patient being able to feel suture.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Prolapse Outcomes</title>
        <description>Positive response to PFDI-20 question #3 regarding the presence of a vaginal bulge (yes) AND the presence of bother (somewhat, moderately or quite a bit).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorbable</title>
            <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)</description>
          </group>
          <group group_id="O2">
            <title>Permanent</title>
            <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Prolapse Outcomes</title>
          <description>Positive response to PFDI-20 question #3 regarding the presence of a vaginal bulge (yes) AND the presence of bother (somewhat, moderately or quite a bit).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorbable</title>
          <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
        </group>
        <group group_id="E2">
          <title>Permanent</title>
          <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Any suture related complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph Kowalski</name_or_title>
      <organization>University of Iowa Hospitals and Clinics</organization>
      <phone>3193561616</phone>
      <email>joseph-kowalski@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

